Musi wa10 Kukadzi 2025, CARsgen Therapeutics yakazivisa kuti munhu wekutanga akarapwa nekurapa kweBCMA CAR-T allogeneic yakagadzirwa papuratifomu yeTHANK-u Plus™, akawana mhinduro yakakwana (sCR) uye kusakwana kwechirwere chemazuva mashoma (MRD) pakuongorora kweZuva-28. Yakagadzirwa mukati mekambani, puratifomu yeTHANK-u Plus™ itekinoroji itsva yeALLOgeneic CAR-T yakagadzirirwa kukunda matambudziko ekuwana mukana wekushandisa CAR-T therapy.
Murwere uyu, akaonekwa aine relapse/refractory multiple myeloma, IgA-λ type (R-ISS Stage II), akambosangana ne combination therapy katatu pamwe chete ne autologous hematopoietic stem cell transplantation. Mushure mekufambira mberi kwechirwere mushure mekurapwa kwazvino, murwere akanyoreswa mukiriniki. Mushure mekuiswa kweCAR T cells padanho repasi zvichienderana nekiriniki protocol, murwere akawana Grade 1 cytokine release syndrome (CRS), iyo yakarapwa zvinobudirira ne antipyretics ne tocilizumab, uye murwere haana kuratidza immune effector cell-associated neurotoxicity syndrome (ICANS) kana zvimwe zviitiko zve immune system zvine chekuita neCAR-T, zvichiratidza kuchengetedzeka kwakanaka.
Kurapa uku kweCAR-T kwakagadzirirwa kurapa relapse/refractory multiple myeloma (R/R MM) uye relapse/refractory plasma cell leukemia (R/R PCL). Mamwe mashoko matsva anotarisirwa muhafu yechipiri yegore rino.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Mareferensi
2.https://www.prnasia.com/
Nguva yekutumira: Kukadzi-11-2025